Hiring in life sciences? Share your open positions with our professional community. Read more Close

Advertisement

[Membranous nephropathy].

Created on 20 Oct 2026

Authors

Maya Machalitza, Elion Hoxha

Published in

Deutsche medizinische Wochenschrift (1946). Volume 151. Issue 21. Pages 1177-1183. Epub Oct 19, 2026.

Abstract

Membranous nephropathy (MN) is an autoimmune disease caused by circulating antibodies (ab) directed against an antigen expressed on glomerular epithelial cells (podocytes), which are a main component of the glomerular filtration barrier. This immune complex formation leads to a loss of selectivity of the filtration barrier and loss of large amounts of proteins in the urine. As a consequence, a nephrotic syndrome develops which is the clinical hallmark of MN. In 75% of patients, the pathogenic antibody is directed against the Phospholipase A2 receptor 1 (PLA2R1). PLA2R1-ab are highly specific for patients with MN allowing in specific clinical situations to make the diagnosis of MN without need of a kidney biopsy. In addition, an increase, or the depletion of PLA2R1-ab is followed by a relapse, or remission of disease, respectively, making them an ideal biomarker for treatment management. Since spontaneous remission of disease is common, immunosuppressive treatment is recommended only for patients with a high risk for progressive loss of kidney function, as well as patients with a low probability to develop remission of disease.

PMID:
42896539
Bibliographic data and abstract were imported from PubMed on 20 Oct 2026.

Read full publication at:
Please sign in to see all details.

Advertisement

Stats

  • Community rating n/a 0 votes
  • Reviewers' rating n/a 0 votes
  • Your rating

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

  • Recommendations n/a n/a positive of 0 vote(s)
  • Views 1
  • Comments 0

Recommended by

  • No recommendations yet.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.

Advertisement